The long-term objective for the new Clinical Immunobiology Correlative Studies Laboratory (CICSL) is to develop into a comprehensive, cutting-edge correlative studies laboratory to support clinical trial and translational research efforts sponsored primarily by Cancer Center investigators at City of Hope. Long-term specific aims include i) continued development and implementation of novel immunological platforms and assays, identified either from external sources or internally, that will support, in a significant way, ongoing and future clinical trials;ii) continued expansion of user base to reflect support, in magnitude and diversity, of the majority of correlative assay needs of Cancer Center investigators;iii) continued evolution and implemention of laboratory operating policies and infrastructure to adhere to GLP practices and ultimately lead to CLIA certification of the laboratory. The principle objective of the laboratory is to develop and implement quantitative methods to evaluate the effect of novel therapies on a patient's immune system, and correlate those effects with treatment outcome to guide the rational development of efficacious therapeutic regimens. The research design and methods for the laboratory are to identify technology platforms that would be most useful and appropriate to evaluate the effect of therapeutic modalities on patients, and to develop assays based on those platforms that could be used to evaluate clinical trials sponsored by Cancer Center investigators. To that end, the laboratory has expertise and infrastructure to develop molecular, flowbased and cell-based assays. The laboratory operates under GLP guidelines, a fact that supports a high standard of operations. During the most recent 10-month reporting period, the CICSL shared resource was used by 13 Cancer Center members from all 5 programs. Peer-reviewed usage represented 79% of total usage. Annual budget for this core is $603,900, of which 47% is institutional funding, 28% is user fees, 15% is from other sources, and 10% ($60,100) is requested from the CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-28
Application #
8208806
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-12-01
Budget End
2011-11-30
Support Year
28
Fiscal Year
2011
Total Cost
$76,459
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Salgia, Ravi; Kulkarni, Prakash; Gill, Prakash S (2018) EphB4: A promising target for upper aerodigestive malignancies. Biochim Biophys Acta Rev Cancer 1869:128-137
Choi, Audrey H; O'Leary, Michael P; Lu, Jianming et al. (2018) Endogenous Akt Activity Promotes Virus Entry and Predicts Efficacy of Novel Chimeric Orthopoxvirus in Triple-Negative Breast Cancer. Mol Ther Oncolytics 9:22-29
Kumar, B; Garcia, M; Weng, L et al. (2018) Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia 32:575-587
Zhou, Jiehua; Lazar, Daniel; Li, Haitang et al. (2018) Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1. Theranostics 8:1575-1590
Ding, Yuan Chun; Adamson, Aaron W; Steele, Linda et al. (2018) Discovery of mutations in homologous recombination genes in African-American women with breast cancer. Fam Cancer 17:187-195
Kurata, Jessica S; Lin, Ren-Jang (2018) MicroRNA-focused CRISPR-Cas9 library screen reveals fitness-associated miRNAs. RNA 24:966-981
Hardwick, Nicola R; Frankel, Paul; Ruel, Christopher et al. (2018) p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. Clin Cancer Res 24:1315-1325
Dietze, Eric C; Chavez, Tanya A; Seewaldt, Victoria L (2018) Obesity and Triple-Negative Breast Cancer: Disparities, Controversies, and Biology. Am J Pathol 188:280-290
Kingsmore, Kathryn M; Vaccari, Andrea; Abler, Daniel et al. (2018) MRI analysis to map interstitial flow in the brain tumor microenvironment. APL Bioeng 2:
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096

Showing the most recent 10 out of 1396 publications